<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="publisher-id">jbpneu</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26578142</article-id>
      <article-id pub-id-type="pmc">4635097</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132015000000126</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter To The Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>BCGitis: A rare complication after intravesical BCG therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Maria Jo&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vaz</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Aurora</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Ros&#xE1;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duarte</surname>
            <given-names>Raquel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Servi&#xE7;o de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.</aff>
      <aff id="aff2"><label>2</label>Centro de Diagn&#xF3;stico Pneumol&#xF3;gico, Vila Nova de Gaia, Portugal</aff>
      <aff id="aff3"><label>3</label>Servi&#xE7;o de Patologia Cl&#xED;nica, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal</aff>
      <aff id="aff4"><label>4</label>Unidade de Investiga&#xE7;&#xE3;o em Epidemiologia - EPIUnit - Instituto de Sa&#xFA;de P&#xFA;blica, Universidade do Porto, Porto, Portugal</aff>
      <aff id="aff5"><label>5</label>Departamento de Epidemiologia Cl&#xED;nica, Medicina Preditiva e Sa&#xFA;de P&#xFA;blica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.</aff>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <volume>41</volume>
      <issue>5</issue>
      <fpage>480</fpage>
      <lpage>481</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>DEAR EDITOR:</title>
      <p>In most cases, bladder carcinoma is located superficially, and the therapeutic approach is usually transurethral resection followed by intravesical therapy (chemotherapy or immunotherapy).<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Initially produced as a vaccine against tuberculosis, BCG-an attenuated strain of <italic>Mycobacterium bovis</italic>-has been widely used in immunotherapy over the last decades.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> Although BCG, used as immunotherapy, has not produced the best results in many cancers, it has been clinically successful in the intravesical treatment of superficial bladder carcinomas.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> Immunotherapy with intravesical BCG eradicates the residual tumor, slows the progression of the disease, reduces the need for cystectomy, and prolongs survival.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> Treatment with BCG is well tolerated by over 95% of patients. The most common side effects are local (inflammation, fever, and pelvic adenopathy). However, although rare, systemic complications have been described.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> Systemic dissemination of the attenuated <italic>M. bovis </italic>bacillus is known as BCGitis. It is more common in individuals with underlying primary or secondary immunodeficiency but can occur in immunocompetent patients.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> There have been only a few reports of cases of respiratory BCGitis.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> Here, we report the case of a patient who was treated with local BCG immunotherapy for urothelial bladder carcinoma and developed a severe <italic>M. bovis</italic> respiratory infection.</p>
      <p>In March of 2013, a 72-year-old male presented with hematuria. The patient also had hypertension, dyslipidemia, cerebrovascular disease (previous stroke), chronic renal failure, and depression. He was being treated with perindopril, indapamide, atorvastatin, acetylsalicylic acid, furosemide, and escitalopram. He had no known drug allergies. Ultrasound revealed a 2.5-cm polyp in the bladder. The patient underwent transurethral resection of the bladder tumor. Histological examination revealed urothelial cell carcinoma (grade 2), without vascular or muscle invasion. Chemotherapy and immunotherapy with intravesical instillation of BCG were started and continued until December of 2013. In February of 2014, the patient presented to the emergency department with a one-week history of dyspnea and productive cough (mucopurulent sputum). He reported no fever, chest pain, hemoptysis, sweating, or other symptoms. On physical examination, he was afebrile, with an increased respiratory rate, hemodynamic stability, and an SpO<sub>2</sub> of 89% on room air. Auscultation revealed bilateral breath sounds, with crackles in both lung bases. There were no other significant changes. Ancillary tests showed a C-reactive protein level of 10 mg/dL, without leukocytosis, together with normal liver and kidney function, overlapping with previous studies of the patient. Blood gas analysis (at a FiO<sub>2</sub> of 24%) showed a pH of 7.43, a PaO<sub>2</sub> of 66 mmHg, a PaCO<sub>2</sub> of 45 mmHg, and an HCO<sub>3</sub> of 29.9 mEq/L. In addition, a chest X-ray showed bilateral diffuse reticulonodular infiltrates. A CT scan of the chest revealed randomly distributed micronodules in the lungs, together with enlargement of the hilar and mediastinal lymph nodes (<xref ref-type="fig" rid="f01">Figure 1</xref>). After having collected sputum for analysis, we started empirical antibiotic treatment with amoxicillin and clavulanic acid. Due to respiratory failure and suspected miliary tuberculosis or diffuse pulmonary metastasis, the patient was admitted to the respiratory ward of the hospital.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Chest CT scan showing randomly distributed micronodules in the lungs, together with enlargement of the hilar and mediastinal lymph nodes.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-05-00480-gf01"/></fig>
</p>
      <p>During hospitalization, microbiological and mycobacteriological cultures of sputum samples were negative. Bronchoscopy revealed bilateral mucopurulent secretions, edema, and diffuse mucosal congestion. Microbiological cultures of bronchial lavage and BAL fluid (BALF) samples were negative. Although the BALF was negative for <italic>M. tuberculosis</italic> on smear microscopy, it tested positive for <italic>M. tuberculosis </italic>complex DNA and for <italic>M. bovis</italic> in cultures. Cytology of the BALF was negative for malignant cells; the patient also tested negative for the viral markers of infection with HIV, HCV, and HBV. Because of the positive result on the nucleic acid amplification test of the BALF, we started tuberculosis treatment with isoniazid, rifampin, pyrazinamide, and ethambutol. Despite improvements in his test results and clinical resolution of the respiratory failure, the patient showed a slight increase in liver enzymes (to less than double the normal values). He underwent upper abdominal ultrasound, which revealed hepatic steatosis with no other abnormalities. In view of the BALF culture positivity for <italic>M. bovis</italic> (which is naturally pyrazinamide-resistant), we suspended the pyrazinamide, and the liver enzyme values normalized thereafter. </p>
      <p>The patient was discharged and continued treatment on an outpatient basis. Future scheduled BCG instillations were suspended. In the initial phase of treatment, the regimen was the isoniazid-rifampin-ethambutol combination, whereas the isoniazid-rifampin combination was used in the maintenance phase. After a total of 6 months of treatment, the patient showed a good response. At this writing, the patient remains under follow-up monitoring of his bladder, without signs of recurrence. The patient gave written informed consent for the reporting of his case.</p>
      <p>Various recent studies have analyzed the outcomes of patients with bladder carcinoma who underwent therapeutic intravesical instillation of BCG. The study conducted by Lamm et al. showed that disseminated BCGitis was extremely rare.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Some studies have reported that, among patients with bladder cancer, there is a relationship between the complications of BCG instillation and a prior diagnosis of tuberculosis, such complications not occurring in patients without a history of tuberculosis and with no evidence of sequelae on chest X-rays.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>
</p>
      <p>In this report, we have presented the case of a male patient without a history of tuberculosis who developed a respiratory infection soon after treatment with intravesical instillation of BCG. The initial diagnostic hypotheses included malignancy. However, after careful investigation, the patient was diagnosed with BCGitis, with no remaining doubt that the lung disease was due to the spread of the BCG used in the treatment of his bladder carcinoma. Despite the rarity of this complication, our case report underscores the need for vigilance and awareness of the possibility of BCG dissemination, given the widespread use of BCG in patients with bladder carcinoma.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manfredi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dentale</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Piergentili</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pultrone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brunocilla</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Tubercular disease caused by bacillus of Calmette-Guerin administered as a local adjuvant treatment of relapsing bladder carcinoma Pathogenetic, diagnostic and therapeutic issues, and literature review</article-title>
          <source>AVFT [serial on the Internet]</source>
          <year>2009</year>
          <volume>28</volume>
          <issue>2</issue>
          <fpage>54</fpage>
          <lpage>60</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://www.revistaavft.com/avft%202%202009/hoja4.html">http://www.revistaavft.com/avft%202%202009/hoja4.html</ext-link>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamm</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>van der Meijden</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brosman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Catalona</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Herr</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
          <article-title>Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer</article-title>
          <source>J Urol</source>
          <year>1992</year>
          <volume>147</volume>
          <issue>3</issue>
          <fpage>596</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">1538436</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harbjerg</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bjerre</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Lilleb&#xE6;k</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Weinreich</surname>
              <given-names>UM</given-names>
            </name>
          </person-group>
          <article-title>Pulmonal bacillus Calmette-Gu&#xE9;rin infection two years after intravesical bacillus Calmette-Gu&#xE9;rin installation [Article in Danish]</article-title>
          <source>Ugeskr Laeger</source>
          <year>2014</year>
          <volume>176</volume>
          <issue>25A</issue>
          <fpage>V07120381</fpage>
          <lpage>V07120381</lpage>
          <pub-id pub-id-type="pmid">25497624</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Saint Martin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Boiron</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Poveda</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Herreman</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Generalized BCG infection after intravesical instillations of Calmette-Gu&#xE9;rin bacillus [Article in French]</article-title>
          <source>Presse Med</source>
          <year>1993</year>
          <volume>22</volume>
          <issue>29</issue>
          <fpage>1352</fpage>
          <lpage>1356</lpage>
          <pub-id pub-id-type="pmid">8248067</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sicard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Steg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leleu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Boccaccio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Abadia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tulliez</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>"BCGitis", a systemic complication of intravesical BCG therapy of bladder tumor [Article in French]</article-title>
          <source>Ann Med Interne (Paris)</source>
          <year>1987</year>
          <volume>138</volume>
          <issue>7</issue>
          <fpage>555</fpage>
          <lpage>556</lpage>
          <pub-id pub-id-type="pmid">3439677</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deeks</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scheifele</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Dawar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ahmandipour</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Serious adverse events associated with bacille Calmette-Gu&#xE9;rin vaccine in Canada</article-title>
          <source>Pediatr Infect Dis J</source>
          <year>2005</year>
          <volume>24</volume>
          <issue>6</issue>
          <fpage>538</fpage>
          <lpage>541</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.inf.0000164769.22033.2c">http://dx.doi.org/10.1097/01.inf.0000164769.22033.2c</ext-link>
          <pub-id pub-id-type="pmid">15933565</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>BCGite: Uma complica&#xE7;&#xE3;o rara da terapia intravesical com BCG</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Maria Jo&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vaz</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Aurora</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff02">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Ros&#xE1;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duarte</surname>
            <given-names>Raquel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff02">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff04">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="aff05">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Servi&#xE7;o de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.</aff>
      <aff id="aff02"><label>2</label>Centro de Diagn&#xF3;stico Pneumol&#xF3;gico, Vila Nova de Gaia, Portugal.</aff>
      <aff id="aff03"><label>3</label>Servi&#xE7;o de Patologia Cl&#xED;nica, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.</aff>
      <aff id="aff04"><label>4</label>Unidade de Investiga&#xE7;&#xE3;o em Epidemiologia - EPIUnit - Instituto de Sa&#xFA;de P&#xFA;blica, Universidade do Porto, Porto, Portugal.</aff>
      <aff id="aff05"><label>5</label>Departamento de Epidemiologia Cl&#xED;nica, Medicina Preditiva e Sa&#xFA;de P&#xFA;blica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.</aff>
    </front-stub>
    <body>
      <sec>
        <title>AO EDITOR:</title>
        <p>Na maioria dos casos, o carcinoma de bexiga situa-se superficialmente, e a abordagem terap&#xEA;utica &#xE9; geralmente a resse&#xE7;&#xE3;o transuretral seguida de terapia intravesical (quimioterapia ou imunoterapia).<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Inicialmente produzido como uma vacina contra a tuberculose, o BCG - uma cepa atenuada de <italic>Mycobacterium</italic>
<italic>bovis</italic> - tem sido amplamente usado na imunoterapia nas &#xFA;ltimas d&#xE9;cadas.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> Embora o uso do BCG na imunoterapia n&#xE3;o tenha produzido os melhores resultados em muitos c&#xE2;nceres, tem-se obtido &#xEA;xito cl&#xED;nico com o uso do BCG no tratamento intravesical de carcinomas superficiais de bexiga.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> A imunoterapia com BCG intravesical erradica o tumor residual, retarda a progress&#xE3;o da doen&#xE7;a, reduz a necessidade de cistectomia e prolonga a sobrevida. <sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> O tratamento com BCG &#xE9; bem tolerado por mais de 95% dos pacientes. Os efeitos colaterais mais comuns s&#xE3;o locais (inflama&#xE7;&#xE3;o, febre e adenopatia p&#xE9;lvica). No entanto, h&#xE1; relatos de complica&#xE7;&#xF5;es sist&#xEA;micas, embora sejam raras.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> A dissemina&#xE7;&#xE3;o sist&#xEA;mica do bacilo <italic>M</italic>. <italic>bovis</italic> atenuado &#xE9; conhecida como BCGite. &#xC9; mais comum em indiv&#xED;duos com imunodefici&#xEA;ncia prim&#xE1;ria ou secund&#xE1;ria subjacente, mas pode ocorrer em pacientes imunocompetentes.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> H&#xE1; apenas alguns relatos de casos de BCGite respirat&#xF3;ria.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> Relatamos aqui o caso de um paciente que recebeu imunoterapia local com BCG para o tratamento de carcinoma urotelial de bexiga e apresentou grave infec&#xE7;&#xE3;o respirat&#xF3;ria por <italic>M</italic>. <italic>bovis</italic>. </p>
        <p>Em mar&#xE7;o de 2013, um homem de 72 anos apresentou hemat&#xFA;ria. O paciente apresentava tamb&#xE9;m hipertens&#xE3;o, dislipidemia, doen&#xE7;a cerebrovascular (acidente vascular cerebral anterior), insufici&#xEA;ncia renal cr&#xF4;nica e depress&#xE3;o. Estava sendo tratado com perindopril, indapamida, atorvastatina, &#xE1;cido acetilsalic&#xED;lico, furosemida e escitalopram. N&#xE3;o tinha alergias medicamentosas conhecidas. A ultrassonografia revelou um p&#xF3;lipo de 2,5 cm na bexiga. O paciente foi submetido a resse&#xE7;&#xE3;o transuretral do tumor da bexiga. O exame histol&#xF3;gico revelou carcinoma de c&#xE9;lulas uroteliais (grau 2), sem invas&#xE3;o vascular ou muscular. O paciente passou a receber quimioterapia e imunoterapia com instila&#xE7;&#xE3;o intravesical de BCG, que prosseguiram at&#xE9; dezembro de 2013. Em fevereiro de 2014, o paciente foi ao pronto-socorro; apresentava dispneia e tosse produtiva (escarro mucopurulento) havia uma semana. O paciente n&#xE3;o referiu febre, dor tor&#xE1;cica, hemoptise, sudorese ou outros sintomas. O exame f&#xED;sico revelou que o paciente estava afebril, com frequ&#xEA;ncia respirat&#xF3;ria aumentada, estabilidade hemodin&#xE2;mica e SpO<sub>2</sub> de 89% em ar ambiente. A ausculta&#xE7;&#xE3;o revelou murm&#xFA;rio vesicular bilateral, com estertores crepitantes em ambas as bases pulmonares. N&#xE3;o havia nenhuma outra altera&#xE7;&#xE3;o significativa. Os resultados de testes complementares revelaram um n&#xED;vel de prote&#xED;na C reativa de 10 mg/dl, sem leucocitose, com fun&#xE7;&#xE3;o hep&#xE1;tica e renal normal, sobrepondo-se a estudos anteriores do paciente. A gasometria (com FiO<sub>2</sub> de 24%) revelou pH de 7,43, PaO<sub>2</sub> de 66 mmHg, PaCO<sub>2</sub> de 45 mmHg e HCO<sub>3</sub> de 29,9 mEq/l. A radiografia de t&#xF3;rax revelou infiltrado reticulonodular difuso bilateral. A TC de t&#xF3;rax revelou micron&#xF3;dulos distribu&#xED;dos aleatoriamente nos pulm&#xF5;es, al&#xE9;m de linfonodomegalia hilar e mediastinal (<xref ref-type="fig" rid="f1">Figura 1</xref>). Ap&#xF3;s a coleta de escarro para an&#xE1;lise, o paciente passou a receber antibioticoterapia emp&#xED;rica (amoxicilina e &#xE1;cido clavul&#xE2;nico). Em virtude de insufici&#xEA;ncia respirat&#xF3;ria e suspeita de tuberculose miliar ou met&#xE1;stase pulmonar difusa, o paciente foi internado na enfermaria de pneumologia do hospital. </p>
        <p>
<fig id="f1" orientation="portrait" position="float"><label>Figura 1.</label><caption><title>TC de t&#xF3;rax mostrando micron&#xF3;dulos distribu&#xED;dos aleatoriamente nos pulm&#xF5;es, al&#xE9;m de linfonodomegalia hilar e mediastinal.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-05-00480-gf01-pt"/></fig>
</p>
        <p>Durante a interna&#xE7;&#xE3;o, os resultados das culturas microbiol&#xF3;gicas e micobacteriol&#xF3;gicas de amostras de escarro foram negativos. A broncoscopia revelou secre&#xE7;&#xF5;es mucopurulentas bilaterais, edema e congest&#xE3;o difusa da mucosa. Os resultados das culturas microbiol&#xF3;gicas de amostras de lavado br&#xF4;nquico e lavado broncoalveolar foram negativos. A baciloscopia do lavado broncoalveolar foi negativa para <italic>M</italic>. <italic>tuberculosis</italic>, mas o teste de DNA do complexo <italic>M</italic>. <italic>tuberculosis</italic> e a cultura para <italic>M</italic>. <italic>bovis</italic> foram positivos. A citologia do lavado broncoalveolar foi negativa para c&#xE9;lulas malignas. Al&#xE9;m disso, os testes dos marcadores virais de infec&#xE7;&#xE3;o por HIV, HCV e HBV foram negativos. Como o resultado do teste de amplifica&#xE7;&#xE3;o dos &#xE1;cidos nucleicos do lavado broncoalveolar foi positivo, o paciente passou a receber tratamento para tuberculose com isoniazida, rifampicina, pirazinamida e etambutol. Apesar da melhora nos resultados dos testes e da resolu&#xE7;&#xE3;o cl&#xED;nica da insufici&#xEA;ncia respirat&#xF3;ria, o paciente apresentou um ligeiro aumento das enzimas hep&#xE1;ticas (para menos que o dobro dos valores normais). O paciente foi submetido a ultrassonografia abdominal superior, que revelou esteatose hep&#xE1;tica sem outras anormalidades. Como a cultura do lavado broncoalveolar fora positiva para <italic>M</italic>. <italic>bovis</italic> (que &#xE9; naturalmente resistente &#xE0; pirazinamida), a pirazinamida foi suspensa, e os valores das enzimas hep&#xE1;ticas ent&#xE3;o voltaram ao normal. </p>
        <p>O paciente recebeu alta hospitalar e passou a ser tratado em regime ambulatorial. As instila&#xE7;&#xF5;es de BCG que j&#xE1; haviam sido programadas foram suspensas. Na fase inicial do tratamento, foi usada a associa&#xE7;&#xE3;o medicamentosa de isoniazida, rifampicina e etambutol, ao passo que na fase de manuten&#xE7;&#xE3;o foi usada a associa&#xE7;&#xE3;o de isoniazida e rifampicina. Ap&#xF3;s um total de 6 meses de tratamento, o paciente apresentou boa resposta. No momento, o paciente est&#xE1; recebendo acompanhamento para a avalia&#xE7;&#xE3;o de sua bexiga, e n&#xE3;o h&#xE1; sinais de recidiva. O paciente assinou um termo de consentimento livre e esclarecido por meio do qual autorizou o relato de seu caso. </p>
        <p>V&#xE1;rios estudos recentes t&#xEA;m analisado os desfechos de pacientes com carcinoma de bexiga submetidos a instila&#xE7;&#xE3;o intravesical terap&#xEA;utica de BCG. O estudo de Lamm et al. mostrou que a BCGite disseminada &#xE9; extremamente rara.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Alguns estudos mostraram que, em pacientes com c&#xE2;ncer de bexiga, h&#xE1; uma rela&#xE7;&#xE3;o entre as complica&#xE7;&#xF5;es da instila&#xE7;&#xE3;o de BCG e um diagn&#xF3;stico pr&#xE9;vio de tuberculose; essas complica&#xE7;&#xF5;es n&#xE3;o ocorrem em pacientes sem hist&#xF3;ria de tuberculose e sem evid&#xEA;ncias de sequelas na radiografia de t&#xF3;rax.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>
</p>
        <p>Neste relato, apresentamos o caso de um paciente do sexo masculino sem hist&#xF3;ria de tuberculose que apresentou infec&#xE7;&#xE3;o respirat&#xF3;ria logo ap&#xF3;s o tratamento com instila&#xE7;&#xE3;o intravesical de BCG. As hip&#xF3;teses diagn&#xF3;sticas iniciais inclu&#xED;ram doen&#xE7;a maligna. No entanto, ap&#xF3;s cuidadosa investiga&#xE7;&#xE3;o, o paciente recebeu diagn&#xF3;stico de BCGite, sem nenhuma d&#xFA;vida de que a doen&#xE7;a pulmonar ocorrera em virtude da dissemina&#xE7;&#xE3;o do BCG usado no tratamento de seu carcinoma de bexiga. Apesar da raridade dessa complica&#xE7;&#xE3;o, nosso relato de caso ressalta a necessidade de aten&#xE7;&#xE3;o &#xE0; possibilidade de dissemina&#xE7;&#xE3;o do BCG, j&#xE1; que o bacilo &#xE9; amplamente usado em pacientes com carcinoma de bexiga. </p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
